Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

SABCS 2015: Dr. Luc Dirix about the first results on anti-PDL1 avelumab

The JAVELIN-1B is a large phase 1 study with anti-PDL1 avelumab. Dr. Lux Dirix presented the first results of the expansion cohort in unselected metastatic breast cancer patients.

  • This program is editorially independent and is financially made possible by

Related items

Congress news

SABCS 2013 trastuzumab biomarker

In the fifth interview news on high levels of immune cells in tumors which may identify breast cancer patients most likely to benefit from Trastuzumab.

Congress news

SABCS 2013 Breastcancer screening

In the fourth interview from San Antonio Dr Robert Smith shares his insights on the benefit of breast cancer screening which appears to be more consistent across studies than previously understood.